Skip to main content
main-content
Top

AMG 510 in NSCLC

This trial is investigating the safety and efficacy of AMG 510 – an agent targeting KRAS – in patients with advanced solid tumors harboring a KRAS G12C mutation.

Phase I trial results

AMG 510 has demonstrated promising efficacy and tolerability in previously treated patients with locally advanced or metastatic KRAS-mutated non-small-cell lung cancer.

Presenting author Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the trial and the next steps for the research (5:34):

Advisory Board member Ross Camidge discusses the implications of this trial in his round-up of key data presented at WCLC 2019:

Findings from the non-small-cell lung cancer cohort were presented at WCLC 2019.

Title: Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRAS G12C inhibitor, evaluated in NSCLC
Presenter: Ramaswamy Govindan, Washington University School of Medicine, St. Louis, Missouri, USA
Sunday, 8 September: 10:40–10:50 (Abstract OA02.02)

Back to the WCLC 2019 conference hub